MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

223.56 -1.2

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

222.15

Massimo

227.07

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

-2.3% downside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2B

11B

Apertura precedente

224.76

Chiusura precedente

223.56

Notizie sul Sentiment di mercato

By Acuity

50%

50%

174 / 360 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 gen 2026, 21:55 UTC

Utili

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 gen 2026, 23:52 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 gen 2026, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 gen 2026, 23:40 UTC

Discorsi di Mercato

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 gen 2026, 22:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 gen 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

22 gen 2026, 21:44 UTC

Utili

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 gen 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 gen 2026, 21:30 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One To Acquire Brex >COF

22 gen 2026, 21:13 UTC

Utili

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 gen 2026, 21:10 UTC

Utili

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 gen 2026, 21:06 UTC

Utili

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Rev $15.58B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q EPS $3.26 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Interest Margin 8.26% >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net $2.13B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Adj EPS $3.86 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Charge-Offs $3.8B >COF

22 gen 2026, 21:05 UTC

Utili

Intuitive Surgical 4Q EPS $2.21 >ISRG

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

-2.3% in calo

Previsioni per 12 mesi

Media 221.55 USD  -2.3%

Alto 265 USD

Basso 170 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

9

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

174 / 360 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat